Last reviewed · How we verify
NewAmsterdam Pharma — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Monotherapy ezetimibe | Monotherapy ezetimibe | phase 3 | Cholesterol absorption inhibitor | NPC1L1 (Niemann-Pick C1-Like 1) | Cardiovascular | |
| Monotherapy obicetrapib | Monotherapy obicetrapib | phase 3 | CETP inhibitor | CETP (cholesterol ester transfer protein) | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Amgen · 1 shared drug class
- Hoffmann-La Roche · 1 shared drug class
- Organon and Co · 1 shared drug class
- University of Oxford · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for NewAmsterdam Pharma:
- NewAmsterdam Pharma pipeline updates — RSS
- NewAmsterdam Pharma pipeline updates — Atom
- NewAmsterdam Pharma pipeline updates — JSON
Cite this brief
Drug Landscape (2026). NewAmsterdam Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/newamsterdam-pharma. Accessed 2026-06-10.